• Home
  • About Us
    • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Management Team
    • Careers
  • For Researchers
    • Paxalisib
    • EVT801
    • Collaborating with Kazia
    • Publications and Presentations
  • For Partners
    • Our Current Partners
    • What We Are Looking For
  • For Patients
    • Accessing Kazia Drug Candidates in Clinical Trials
    • Accessing Kazia Drug Candidates for Compassionate Use
    • Resources for Patients
  • For Investors
    • ASX Announcements
    • SEC Filings
    • Corporate Presentations
    • Annual Reports
    • Financial Reports
    • AGM
    • Investor Newsletters
    • Corporate Governance
    • Shareholder Services
  • Media Centre
    • Overview
    • Latest News
    • Video
    • Coverage
  • Contact
    • Contact Us
    • Subscribe to email alerts
Kazia Therapeutics Limited
Heading &
Sub-heading can be edited through HQI
Home > Media Centre > Latest News
  • Overview
  • Latest News
  • Video
  • Coverage

Latest News

Filter by Year:2023 2022 2021 2020 
15-Jun-2021
Kazia Enters Clinical Collaboration With Cornell University For Phase Ii Clinical Study Using Paxalisib In Combination With Ketogenic Diet For Glioblastoma
7-Jun-2021
Study Of Paxalisib In Primary Cns Lymphoma At Dana-Farber Cancer Institute Enrols First Patient
19-Apr-2021
Kazia Licenses Global Rights To Evt801, A Novel, First-In-Class, Clinic-Ready, Vegfr3 Inhibitor, From Evotec Se
29-Mar-2021
Kazia Licenses Rights To Paxalisib In Greater China To Simcere, A Leading Chinese Pharmaceutical Company
1-Mar-2021
Kazia Licenses Cantrixil, A Clinical-Stage, First-In-Class Ovarian Cancer Drug Candidate, To Oasmia Pharmacetical Ab
7-Jan-2021
Gbm Agile Pivotal Study Commences Recruitment To Paxalisib Arm
20-Dec-2020
Kazia Therapeutics Limited Appendix 4D Half-year report
  • Previous 
  • 1
  • 2
  • 3
  • 4
  • 5
 

Quick Links

Contact Us

Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia

info@kaziatherapeutics.com
https://www.kaziatherapeutics.com

Subscribe to Email Alerts

Which of the following group do you best fit?

 

Email Alerts

Subscribe to our Email Alerts

Follow Us

Copyright © Kazia Therapeutics Limited
Site Map Privacy Search
Design byspatialdesign Site by